Helius Medical Technologies, Inc. Class A (HSDT) Dividend History

Helius Medical Technologies, Inc. is a neurotech company focused on developing and commercializing non-invasive neuromodulation therapies to improve brain function and recovery. Their flagship product, the Portable Neuromodulation Stimulator (PoNS), aims to enhance neuroplasticity and aid in rehabilitation for patients with neurological conditions such as traumatic brain injury and stroke. The company emphasizes innovative solutions to address unmet needs in neurological healthcare.

642 Newtown Yardley Road, Newtown, PA, 18940
Phone: 215-944-6100
Website: https://www.heliusmedical.com

Dividend History

Helius Medical Technologies, Inc. Class A currently does not pay dividends

Company News

Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering

Helius Medical Technologies, Inc. announced the pricing of its public offering of 2,768,600 shares of Class A common stock and warrants to purchase up to 2,768,600 shares of common stock at a combined public offering price of $3.27 per share and accompanying warrants. The offering is expected to raise gross proceeds of $9.1 million.

GlobeNewswire Inc.
Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target

Helius Medical Technologies has exceeded its initial enrollment target for its stroke registrational program, with 128 participants enrolled as of December 31, 2024. The company expects to reach the maximum enrollment of 150 participants by the end of January 2025 and is on track to submit for FDA authorization for the PoNS device in the stroke indication in the second quarter of 2025.

GlobeNewswire Inc.
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, a neurotech company, announced its plans to participate in The ThinkEquity Conference on October 30, 2024, where management will present and hold one-on-one investor meetings.

GlobeNewswire Inc.
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

Helius Medical Technologies announced updates on reimbursement determinations from CMS for its PoNS device. CMS set the reimbursement rate for the PoNS Mouthpiece at $2,963.30, which Helius plans to challenge. CMS deferred the final determination for the PoNS Controller to the next cycle.

GlobeNewswire Inc.
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke

-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke -- -- In Canada, an additional study on the use of Portable Neuromodulation Stimulator (PoNS®) Therapy to treat stroke has started to support Canadian reimbursement and U.S. approval for stroke --

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:46:41 UTC